UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August 5~~September 19, 2022

Biohaven Pharmaceutical Holding Company Ltd.

(Exact name of registrant as specified in its charter)


British Virgin Islands	001-38080	Not applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of each exchange on which registered
Common Shares, no par value	BHVN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On ~~August 5~~September 19, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the “~~Registrant~~Company”) ~~issued~~filed a ~~press~~prospectus ~~release~~supplement ~~announcing~~to its ~~financial~~Registration ~~results~~Statement ~~for~~on Form S-3 filed with the ~~second~~U.S. ~~quarter~~Securities ~~ended~~and ~~June~~Exchange ~~30,~~Commission ~~2022~~(the “Commission”) (No. A333-253946) ~~copy~~(the of“Registration ~~this~~Statement”), ~~press~~under ~~release~~the isSecurities ~~furnished~~Act ~~herewith~~of 1933, as ~~Exhibit~~amended, ~~99.1~~with respect to ~~this~~the ~~Current~~resale ~~Report~~by ~~and~~the isselling ~~incorporated~~shareholder ~~herein~~named therein of 493,254 common shares, no par value, of the Company that were issued by ~~reference~~the Company to such selling shareholder as share consideration in connection with the transactions and business arrangements described therein.

In ~~accordance~~connection with ~~General~~filing ~~Instruction B.2.~~ of ~~Form~~such ~~8-K~~prospectus supplement, the ~~information~~Company inis ~~this~~filing ~~Item~~a ~~2.02,~~legal ~~and~~opinion as Exhibit 99No. 5.1 ~~hereto,~~to ~~shall~~this ~~not~~Current beReport ~~deemed~~on ~~“filed”~~Form ~~for purposes of Section 18 of the Securities Exchange Act of 1934~~8-K, aswhich ~~amended~~is ~~(the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed~~ incorporated by reference ininto ~~any of~~ the ~~Registrant’s~~Registration filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filingStatement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number*						Exhibit Description
Exhibit Number						Exhibit Description
99.1						Press Release, dated August 5, 2022, "Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments"
5.1						Opinion of Maples & Calder.
23.1						Consent of Maples & Calder (included in Exhibit 5.1).
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

* The XBRL instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~August 5~~September 19, 2022


Biohaven Pharmaceutical Holding Company Ltd.

By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

Filing Compare · Biohaven Pharmaceutical Holding Co Ltd.